Barbell Medicine Podcast

Every week there's a new headline saying men are losing testosterone. A quarter of men now start testosterone replacement therapy without ever getting their blood tested. The supplement aisle is full of boosters that either do nothing or contain undisclosed steroids. And the lab test that gets everybody to the pharmacy? Half of low results normalize on their own.
In Episode 1 of the Signal launch series, Dr. Jordan Feigenbaum and Dr. Austin Baraki (both MDs and strength coaches) walk through the three-layer problem with how testosterone gets diagnosed and treated in 2026, then take apart the "testosterone is crashing" headline with the most current data available, including a 2025 meta-analysis of more than one million men.
Timestamps
0:00 Mark's story: treating the number, not the patient
1:18 Welcome to the Barbell Medicine Podcast
1:41 Problem 1: A quarter of men start TRT with no lab work
3:36 Problem 2: Why testosterone boosters do not work (and what is in them)
13:40 Problem 3: Why one low testosterone lab is not a diagnosis
19:19 Setup: Is the testosterone crisis headline real?
20:04 The MMAS data and the 1%-per-year number
20:52 The 2025 meta-analysis of over 1 million men
22:02 Why the headline is inflated: three causes
22:27 Cause 1: The testing method changed (immunoassay to mass spec)
25:58 Cause 2: BMI cannot see visceral fat
29:37 The Nyante study: when you fix both problems, the decline vanishes
33:58 What this actually means for you
37:05 The broken testosterone system, summarized
38:24 Five takeaways from this episode
39:14 Next week: How testosterone actually works
39:39 About Signal and credits

What you'll learn in this episode:
 Why 25% of new TRT prescriptions are written without any pre-treatment lab work (JAMA, 2015)
What actually happens when researchers test 50+ "testosterone booster" supplements (spoiler: 12% are contaminated with undisclosed steroids)
Why a single low testosterone reading is not a diagnosis, and the Massachusetts Male Aging Study data that proves it
The real size of the population-level testosterone decline (much smaller than 1% per year)
Why BMI cannot see the visceral fat that is driving most of the genuine decline
The Nyante study that shows the decline essentially vanishes when you use an accurate test and measure waist circumference
Five practical takeaways you can apply before your next lab draw

This is Episode 1 of a four-part series built around our upcoming book, Signal. Over the next four weeks we cover what testosterone actually is, how to tell when it is genuinely low, what is really driving population-level changes, and what the evidence says you can do about it.
Next Steps
Check out our new book, Signal (coming soon)
For evidence-based resistance training programs: barbellmedicine.com/training-programs
For individualized training consultation: barbellmedicine.com/coaching
Explore our full library of articles on health and performance: barbellmedicine.com/resources
To consult with Drs. Baraki or Feigenbaum email us at [email protected]
To support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.com
Resources

Baillargeon, J., et al. (2015). Trends in Androgen Prescribing in the United States, 2001–2011. JAMA Intern Med, 175(8), 1413–1415. — 25% no preceding lab; post-prescription monitoring gap.

Rao, P.K., et al. (2017). Trends in Testosterone Replacement Therapy Use from 2003 to 2013 among Reproductive-Age Men in the United States. J Urol, 197(4), 1121–1126. — Prescription volume growth.

Selinger, S., & Thallapureddy, A. (2024). Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018–2022. PLoS One, 19(8), e0309160. — Recent prescribing data, 3-4 million estimate.

Vesper, H.W., et al. (2015). Serum Total Testosterone Concentrations in the US Household Population from the NHANES 2011–2012 Study Population. Clin Chem, 61(12), 1495–1504. — Population testosterone levels, NHANES data.

Clemesha, C.G., et al. (2020). "Testosterone Boosting" Supplements Composition and Claims Are Not Supported by the Academic Literature. World J Men's Health, 38(1), 115–122. — 62% no published data, 10% decreased T.

Tucker, J., et al. (2018). Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US FDA Warnings. JAMA Network Open, 1(6), e183337. — 12% adulterated with undisclosed steroids.

Trost, L.W., & Mulhall, J.P. (2016). Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials. J Sex Med, 13(7), 1029–1046. — Half of low results normalize on repeat.

Travison, T.G., et al. (2008). The Natural History of Symptomatic Androgen Deficiency in Men: Onset, Progression, and Spontaneous Remission. JCEM. MMAS data — 50%+ spontaneous normalization.

Travison, T.G., et al. (2007). A Population-Level Decline in Serum Testosterone Levels in American Men. JCEM, 92(1), 196–202. — Original MMAS secular decline, 15–20% lower across cohorts.
Santi, D., et al. (2025). Meta-analysis of secular trend in total testosterone levels, 1971–2024. 1,256 studies, N > 1,000,000. — 0.56%/year adjusted; LH parallel decline; mass spec subgroup no significant decline.
 Methods note on the ~0.56% per year figure cited in this episode: the Santi paper does not report a single percentage rate. The headline adjusted meta-regression coefficient (−0.6 nmol/L/year) is inflated by the random-effects weighting scheme and is not a biological rate. The 0.5–0.6% per year approximation comes from the pre-2000 stratified subgroup (Fig. 5, coefficient −0.1 nmol/L/year) divided by the dataset mean of 18.5 nmol/L. The post-2000 stratum runs larger (~1.1%), and the age-stratified coefficients in Table 5 cluster in the 0.4–0.9% range. The mass spectrometry subgroup (Table 3, Group 4) showed no significant trend (p = 0.845). The episode uses the conservative end of this range as the most defensible estimate of the real population-level rate after accounting for assay drift.

Nyante, S.J., Graubard, B.I., Li, Y., McQuillan, G.M., Platz, E.A., Rohrmann, S., Bradwin, G., & McGlynn, K.A. (2012). Trends in sex hormone concentrations in US males: 1988–1991 to 1999–2004. Int J Androl, 35(3), 456–466. doi: 10.1111/j.1365-2605.2011.01230.x. — Archived NHANES samples, same platform, waist circumference added; no significant decline in total or free testosterone.

Our Sponsors:
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Factor: http://factormeals.com/bbm50off
* Check out Quince: https://quince.com/bbm

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

A 43-year-old man starts exercising and ends up in the ER with a CK over 100x the upper limit of normal. His doctor says it’s from training. We don’t think so. In this episode, Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through the full case — history, labs, diagnosis, and what actually went wrong — then break down the mechanisms behind the answer, the nocebo research, and what the brand-new 2026 guidelines mean for the 40 million Americans on a drug class you’ve definitely heard of.

We also cover the STOMP trial (do statins actually impair strength gains?), the SAMSON trial (how much of statin intolerance is nocebo?), the difference between myalgia, myositis, and rhabdomyolysis, Austin’s clinical approach to a patient whose strength is declining on a statin, and the treatment escalation pathway for statin-intolerant patients including bempedoic acid, PCSK9 inhibitors, and inclisiran. Plus, where GLP-1 receptor agonists like tirzepatide fit into the cardiovascular risk picture.
Timestamps
0:00 — A 43-year-old man is getting weaker, not stronger
2:09 — Taking the history: Medications, lifestyle, and red flags
12:53 — The labs come back: CK at 18,979
16:05 — Metabolic syndrome and the modern treatment approach
23:15 — Rhabdomyolysis: What it is and why it’s dangerous
29:50 — Final diagnosis and what went wrong with the medications
37:15 — 2026 ACC lipid guidelines: What changed
40:32 — Three mechanisms: How statins affect muscle
47:02 — The nocebo effect and the SAMSON trial
54:17 — Do statins impair training? The STOMP trial
1:00:30 — Who’s at highest risk for statin muscle problems
1:07:36 — What happened to the patient and options if this is you
1:14:12 — Five takeaways

Five Takeaway
 Statin myopathy is real but relatively uncommon. The excess symptom rate above placebo is roughly 1–5% in controlled trials. But in exercising patients, especially on combination therapy, the risk can be higher.
There are three proposed mechanisms: reduced energy production from CoQ10 depletion, compromised muscle cell membranes from isoprenoid loss, and accelerated protein breakdown from calcium leak via the ryanodine receptor. Exercise amplifies all three, but the vast majority of people compensate.
If you’re on a statin and your strength is going down, talk to your doctor before stopping the medication or changing your training. A CK test can help separate a drug problem from a programming problem
The 2026 ACC guidelines list vigorous exercise as a risk factor for statin-associated muscle symptoms for the first time. They also provide statin-intolerant patients a clear escalation pathway: bempedoic acid, ezetimibe, PCSK9 inhibitors, and more.
Lower is better for LDL. There’s a 33% relative reduction in cardiovascular events at <55 vs. 70 mg/dL. Lower for longer. Healthy lifestyle changes plus effective lipid-lowering therapy are among the best things you can do for cardiovascular risk.

Next Steps
For evidence-based resistance training programs: barbellmedicine.com/training-programs
For individualized training consultation: barbellmedicine.com/coaching
Explore our full library of articles on health and performance: barbellmedicine.com/resources
To consult with Drs. Baraki or Feigenbaum email us at [email protected]
To support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.com

 Resources
Training Plateau Action Plan (free):
https://www.barbellmedicine.com/training-plateau-action-plan/
Fish oil episode:
https://open.spotify.com/episode/4kRtXZBMZWKkZPDdIKpu1S
Lp(a): https://www.barbellmedicine.com/blog/lipoprotein-a-testing-and-treatment/

Guidelines
Blumenthal RS, Morris PB, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423

Case
László A, et al. Exercise and Statin-Fibrate Combination Therapy-Caused Myopathy. BMC Research Notes. 2013;6:52. https://pubmed.ncbi.nlm.nih.gov/23388500/
 
LDL Targets
Lee YJ, et al. (Ez-PAVE) Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. NEJM. 2026. PMID: 41910315

Mechanisms of Statin Myopathy
Meador BM, Huey KA. Statin-Associated Myopathy and Its Exacerbation with Exercise. Muscle Nerve. 2010;42(4):469–479. https://pubmed.ncbi.nlm.nih.gov/20878737/

Safitri N, et al. Statin-Induced Rhabdomyolysis: Mechanisms, Risk Factors, Management. Drug Healthc Patient Saf. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8593596/

Molinarolo S, et al. Cryo-electron microscopy reveals sequential binding and activation of Ryanodine Receptors by statin triplets. Nat Commun. 2025;16(1):11508. doi:10.1038/s41467-025-66522-0

Thompson PD, et al. Lovastatin Increases Exercise-Induced Skeletal Muscle Injury. Metabolism. 1997;46(10):1206–1210

Nocebo Effect and Statin Intolerance
Wood FA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects (SAMSON). NEJM. 2020;383(22):2182–2184. https://pmc.ncbi.nlm.nih.gov/articles/PMC8453640/

Khan S, et al. Does Googling Lead to Statin Intolerance? Int J Cardiol. 2018;262:25–27. https://pubmed.ncbi.nlm.nih.gov/29706390/

Gupta A, et al. Adverse Events Associated with Unblinded, but Not with Blinded, Statin Therapy in the ASCOT-LLA. Lancet. 2017;389(10088):2473–2481. https://pubmed.ncbi.nlm.nih.gov/28476288/

Moon JC, et al. Examining the Nocebo Effect of Statins through the FDA AERS. Circ Cardiovasc Qual Outcomes. 2021;14(1):e007480. https://pubmed.ncbi.nlm.nih.gov/33161769

Statins and Exercise Outcomes
Parker BA, et al. Effect of Statins on Skeletal Muscle Function (STOMP). Circulation. 2013;127(1):96–103. https://pubmed.ncbi.nlm.nih.gov/23183941/

Parker BA, Thompson PD. Effect of Statins on Skeletal Muscle: Exercise, Myopathy, and Muscle Outcomes. Exerc Sport Sci Rev. 2012;40(4):188–194. https://pmc.ncbi.nlm.nih.gov/articles/PMC3463373/

Mikus CR, et al. Simvastatin Impairs Exercise Training Adaptations. JACC. 2013;62(8):709–714. https://pubmed.ncbi.nlm.nih.gov/23583255/

Slade JM, et al. The Impact of Statin Therapy and Aerobic Exercise Training. Am Heart J Plus. 2021;10:100028. https://pmc.ncbi.nlm.nih.gov/articles/PMC8477381/

Gui Y, et al. Efficacy and Safety of Statins and Exercise Combination Therapy. Eur J Prev Cardiol. 2017;24(9):907–916. DOI: 10.1177/2047487317691874 

Genetic Susceptibility
SEARCH Collaborative Group. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. NEJM. 2008;359(8):789–799

Autoimmune Myopathy
Barkhordarian M, et al. Statin-Induced Autoimmune Myopathy. Am J Case Rep. 2024;25:e944261. https://pubmed.ncbi.nlm.nih.gov/39219126/

Statin-Fibrate Interactions
Jones PH, Davidson MH. Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin vs Gemfibrozil + Any Statin. Am J Cardiol. 2005;95(1):120–122

Bruckert E, et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy (PRIMO Study). Cardiovasc Drugs Ther. 2005;19(6):403–414

Sinzinger H, O’Grady J. Professional Athletes Suffering from Familial Hypercholesterolaemia Rarely Tolerate Statin Treatment. Br J Clin Pharmacol. 2004;57(4):525–528

Tirzepatide and GLP-1 Agonists
Al-kuraishy HM, et al. The mechanistic role of tirzepatide in atherosclerosis. Int J Biol Macromol. 2025;329(1). https://doi.org/10.1016/j.ijbiomac.2025.147734

Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11704219/

Hamidi H, et al. Effect of tirzepatide on coronary atherosclerosis progression (T-Plaque trial design). Am Heart J. 2024;278:24–32. doi:10.1016/j.ahj.2024.08.015

Fish Oil and Omega-3 Fatty Acids
Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl (REDUCE-IT). NEJM. 2019;380:11–22. https://pubmed.ncbi.nlm.nih.gov/30415628/

Abdelhamid AS, et al. Omega-3 Fatty Acids for Prevention of Cardiovascular Disease. Cochrane Database Syst Rev. 2020. https://pubmed.ncbi.nlm.nih.gov/32114706/

Manson JE, et al. Marine n-3 Fatty Acids and Prevention of CVD and Cancer (VITAL). NEJM. 2019;380:23–32. https://pubmed.ncbi.nlm.nih.gov/30415637/
 

Myopathy Classification
Selva-O’Callaghan A, et al. Statin-Induced Myalgia and Myositis: Pathogenesis and Clinical Recommendations. Expert Rev Clin Immunol. 2018;14(3):215–224. https://pmc.ncbi.nlm.nih.gov/articles/PMC6019601/

Our Sponsors:
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Factor: http://factormeals.com/bbm50off
* Check out Quince: https://quince.com/bbm

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

In 2022, researchers conducted the most rigorous systematic review ever performed on overtraining syndrome — looking specifically for controlled studies that documented a human transitioning from a healthy training state to an overtrained state. Zero studies met those criteria.
 
The word "overtrained" appears in coaching certifications, wearable device dashboards, and clinical sports medicine guidelines — and in each context it means something different. That definitional chaos has consequences: it delays real diagnoses, produces nocebo effects with measurable physiological outcomes, and leads athletes to reduce training they didn't need to reduce.

In this episode, Drs. Jordan Feigenbaum and Austin Baraki work through the full evidence base on overtraining syndrome — the taxonomy, the attempted studies, the six competing mechanistic theories, the biomarker failures, and what's actually happening when a lifter can't make progress.
 
Timestamps:

0:00 Cold open — the zero-studies finding
1:21 Why "overtrained" does four different jobs simultaneously
16:10 The FOR / NFOR / OTS taxonomy
19:43 The supercompensation model — borrowed from endurance, never validated for resistance training
32:28 Austin's clinical differential for fatigue and declining performance
36:17 RT evidence — what happens when researchers try to induce OTS through lifting
43:19 Austin — what actually drives the complaints he sees in practice
47:30 Six theories for what causes overtraining syndrome
1:01:09 The biomarker problem — why the T:C ratio and cortisol don't work
1:05:09 What your wearable is actually measuring (and what it isn't)
1:09:28 Austin — testosterone levels in trained athletes and when to act
1:13:40 Heart rate variability — limitations for strength training
1:15:36 Session RPE — the monitoring tool that actually works
1:17:31 How common is overtraining syndrome, really?
1:23:04 Three failure modes — what's actually happening when lifters say they feel overtrained
1:32:14 Austin — what a proper medical workup looks like
1:34:22 Outro

What we cover:

The definition problem — why a single word is doing four incompatible jobs simultaneously, and why that matters clinically and practically.
The taxonomy — functional overreaching, nonfunctional overreaching, and overtraining syndrome as points on a continuous variable that can only be identified after the fact, not at presentation.
The supercompensation model — where it came from, why it fails to describe how resistance training adaptation actually works, and how applying it too literally produces both overloading and underloading errors at the same time.
Austin's clinical differential — what a physician actually works through when a patient presents with fatigue and declining performance, and where overtraining syndrome actually sits on that list.
What resistance training research shows — including 140 maximal singles, 90 working sets per week, and daily 1-rep max attempts. No study has cleanly induced overtraining syndrome through resistance training. The hormonal data went in the opposite direction from what the endurance overtraining model predicts.
Six mechanistic theories — glycogen depletion, serotonin/BCAA, autonomic imbalance, central governor, HPA axis dysregulation, and Armstrong's complex systems framework. Each one is partially supported and each falls short.
The biomarker problem — resting cortisol is normal in 75%+ of OTS cases, the testosterone to cortisol ratio has never been validated against clinical outcomes as an individual diagnostic, and HRV recovery in strength training lags physical recovery by up to 30 hours.
Austin on wearables — including a clinical pattern he's seeing with GLP-1 receptor agonists: wearable scores indicating deterioration when the clinical picture is actually fine.
Session RPE as the real tool — why session RPE trending upward at stable training load is a more reliable signal of load-recovery mismatch than any biomarker currently used.
Prevalence and confounders — the 60% figure, why it almost certainly captures all three FOR/NFOR/OTS categories plus REDS, depression, and illness, and why the residual true training-load-induced OTS in an otherwise healthy athlete may be vanishingly rare.
Three failure modes — the three things Jordan actually sees in practice when lifters present saying they feel overtrained, and how to distinguish between them using session RPE.
The medical workup — Austin's practical walkthrough of what to assess when programming and lifestyle changes don't move the needle, including iron deficiency (ferritin testing caveats, lab reference range problems), sleep apnea, post-viral syndromes, and hormone panels done correctly.

Next Steps:

For evidence-based resistance training programs: barbellmedicine.com/training-programs

For individualized training consultation: barbellmedicine.com/coaching

Explore our full library of articles on health and performance: barbellmedicine.com/resources

To consult with Drs. Baraki or Feigenbaum email us at [email protected]

For ad free listening and exclusive discounts, become a Barbell Medicine Plus subscriber at https://barbellmedicine.supercast.com/

 Resources
 
Taxonomy / Definitions
Meeusen et al. (2013)
European College of Sport Science / ACSM consensus statement on FOR, NFOR, and OTS taxonomy. Defines OTS as a diagnosis of exclusion.
https://pubmed.ncbi.nlm.nih.gov/23247672/

Meeusen et al. (2006)
"Often only after a period of complete rest" — the retrospective nature of distinguishing NFOR from OTS.
https://pubmed.ncbi.nlm.nih.gov/23016079/

Nocebo Effects in Sport
2024 Systematic Review
Nocebo effects in sport were approximately twice the magnitude of placebo effects on performance across 20 studies.
https://pubmed.ncbi.nlm.nih.gov/38999724/

Stress-Recovery-Adaptation Model
Original general adaptation syndrome / stress physiology work in Nature. Foundational source the SRA model was derived from — not a sports science paper.
https://www.nature.com/articles/138032a0

Multi-system adaptation timescales; critique of single-wave supercompensation model.
https://pubmed.ncbi.nlm.nih.gov/3057313/

Multi-system adaptation timescales; further critique of the SRA "window of opportunity" model.
https://pubmed.ncbi.nlm.nih.gov/15044685/

Lack of empirical support for the supercompensation "window of opportunity" in real training scenarios.
https://pubmed.ncbi.nlm.nih.gov/29189930/

Resistance Training and OTS
Grandou et al. (2020)
Systematic review: 22 studies on resistance training overtraining. 10 showed zero performance decline under deliberate overload. No reliable biomarker established for RT overtraining; sustained performance drop is the only consistent signal.
https://pubmed.ncbi.nlm.nih.gov/31313309/

Coleman et al. (2024)
9-week supervised high-volume RT protocol (~90 sets/week). No OTS criteria met. Ceiling for resistance training-induced OTS is considerably higher than commonly implied.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10809978/

Zourdos et al. (2016)
Case series: 3 competitive strength athletes performed daily 1RM squat for 30 consecutive days. All three improved.
https://pubmed.ncbi.nlm.nih.gov/26816276/

Daily 1RM Bench Press Study
7 athletes attempted a true 1RM bench press every day for 38 days. All improved despite day-to-day fluctuation.
https://www.thefreelibrary.com/Efficacy+of+Daily+One-Repetition+Maximum+Bench+Press+Training+in...-a0828317501

3 weeks of daily loading; volume arm hypertrophied. Daily frequency did not produce overtraining; volume drives hypertrophy, not frequency alone.
https://pubmed.ncbi.nlm.nih.gov/27875635/

Fry et al. (1994) — Overreaching Protocol
Original resistance overreaching induction: 10×1 at 100% 1RM daily for 14 days. 1RM dropped ~12 kg. Hormonal response was opposite to endurance OTS profile (cortisol decreased, testosterone slightly increased).
https://pubmed.ncbi.nlm.nih.gov/7808252/

Fry et al. (1994) — Endurance Biomarkers
Endurance OTS biomarkers (T:C ratio) do not apply to high-intensity resistance training overreaching.
https://pubmed.ncbi.nlm.nih.gov/9843563/

Fry et al. (2006)
Same overreaching protocol with muscle biopsies. Beta-2 adrenergic receptor density in vastus lateralis decreased 37%. Orthopedic ceiling hypothesis: structural limits intervene before neuroendocrine axis fully desensitizes.
https://pubmed.ncbi.nlm.nih.gov/16888042/

Raastad et al. (2001)
Daily submaximal leg training for 2 weeks; 1RM increased 6%. Intensity (not frequency) is the necessary ingredient for overreaching in resistance training.
https://pubmed.ncbi.nlm.nih.gov/11394254/

Margonis et al. (2007)
12-week progressive RT peaking at ~14 tonnes/week. Significant 1RM decrements not restored after 6-week taper — the only resistance training study to approach true OTS criteria.
https://pubmed.ncbi.nlm.nih.gov/17697935/

HPA Axis / Biomarkers

Cadegiani & Kater (2017) — EROS Study
Resting cortisol is normal in ≥75% of OTS studies. Reduced pituitary ACTH output (not adrenal failure) is the upstream dysregulation in OTS. "Adrenal fatigue" is mechanistically backwards.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5722782/

EROS Study — Extended Findings
Further EROS study data on HPA axis dysregulation patterns in OTS.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6590962/

Testosterone: acute 30% drops occur routinely after a marathon and normalize within days. Never validated as an individual OTS diagnostic.
https://pubmed.ncbi.nlm.nih.gov/3744643/

Saw et al. (2016)
56-study systematic review of athlete monitoring tools. Subjective measures (mood, perceived fatigue, sleep quality) tracked training load changes with greater sensitivity than objective markers including hormones, resting HR, and HRV.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4789708/

Meeusen et al. (2004/2010) — Two-Bout Exercise Protocol
Two maximal incremental tests 4 hours apart with serial blood draws. OTS athletes show blunted ACTH/prolactin response to second bout; NFOR athletes show exaggerated response. Most validated objective test available; not a field tool.
https://pubmed.ncbi.nlm.nih.gov/18703548/

HRV as a Monitoring Tool
HRV for OTS detection: weak data, foundational work done in cyclists and triathletes only.
https://pubmed.ncbi.nlm.nih.gov/23852425/

Strength recovery occurred ~30 hours after heavy loading; HRV had not normalized at 60 hours. Using HRV as a daily training prescription tool in strength athletes is an untested assumption.
https://pubmed.ncbi.nlm.nih.gov/21273908/

Session RPE and Monitoring
Foster et al. (1998)
Session RPE method: training load quantified as RPE × session duration. Key monitoring metric throughout the episode.
https://pubmed.ncbi.nlm.nih.gov/9662690/

Soreness, mood, and motivation relative to training load as monitoring signals.
https://pubmed.ncbi.nlm.nih.gov/38321325/

Prevalence
Morgan et al. (1987)
The commonly cited 60% OTS prevalence figure. Retrospective self-report using the term "staleness," conducted before the current taxonomy existed. Almost certainly captures all three tiers of the FOR/NFOR/OTS continuum.
https://pubmed.ncbi.nlm.nih.gov/3676635/

Confounders: PED Use
Anonymous Survey Data (2011)
29% of Track and Field World Championship athletes admitted PED use; 45% at Pan-Arab Games.
https://core.ac.uk/download/pdf/109992897.pdf

Lippi et al. (2015)
WADA detects PED use in only 1–2% of samples; USADA detection rate <1%. Elite athlete PED use is substantially underreported in the OTS literature.
https://www.nature.com/articles/517529a

Confounders: Psychiatric Conditions

Armstrong & VanHeest (2002)
Overlap between OTS and major depression. Depression can produce every OTS symptom; any OTS workup without a formal depression screen is incomplete.
https://pubmed.ncbi.nlm.nih.gov/11839081/

Confounders: Energy Availability

Cadegiani et al. (2021)
86% of OTS studies showed co-occurrence of reduced energy availability with OTS-like presentation.
https://pubmed.ncbi.nlm.nih.gov/34181189/

Autoregulation and RPE — Part I
Barbell Medicine blog post on autoregulation and RPE-based programming.
https://www.barbellmedicine.com/blog/autoregulation-and-rpe-part-i/

Training Plateau Action Plan
Barbell Medicine practical guide for diagnosing and addressing training plateaus.
https://www.barbellmedicine.com/training-plateau-action-plan/

Injury / Rehab Coaching Questionnaire
https://www.barbellmedicine.com/coaching-questionnaire-injury-rehab/

Our Sponsors:
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Factor: http://factormeals.com/bbm50off
* Check out Quince: https://quince.com/bbm

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

In this free preview of the March 2026 Direct Line AMA. Drs. Feigenbaum and Baraki cover: VO2 max versus cardiorespiratory fitness for longevity (are Peter Attia’s targets evidence-based? — with Goodhart’s Law and the JAMA evidence), what GLP-1 medications actually cost now via manufacturer programs ($149–449/month), and whether 7,000–10,000 daily steps actually meet the bar for cardiovascular training.

Full episode for Barbell Medicine Plus subscribers at https://barbellmedicine.supercast.com/

Timestamps:
0:00 — Introduction
3:26 — VO2 Max vs. Cardiorespiratory Fitness for Longevity
14:11 — GLP-1 Costs: What you should actually be paying now
21:43 — Is Walking Enough for Cardiovascular Health?

Next Steps:

For evidence-based resistance training programs: barbellmedicine.com/training-programs

For individualized training consultation: barbellmedicine.com/coaching

Explore our full library of articles on health and performance: barbellmedicine.com/resources

To consult with Drs. Baraki or Feigenbaum email us at [email protected]

Resources:

JAMA Network Open — Cardiorespiratory Fitness & Long-term Mortality (Mandsager et al.) — Exercise capacity (METs) and longevity — the foundational CRF/mortality study cited in the episode https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428
JAMA — Blair et al. — Physical fitness and all-cause mortality: a prospective study of healthy men and women https://jamanetwork.com/journals/jama/fullarticle/379243
Barbell Medicine Vital Five — Multi-modal CRF benchmarks and longevity targets https://www.barbellmedicine.com/vital-5-action-plan/
Lilly Direct — Zepbound (tirzepatide) — Manufacturer direct program ($299–449/month) https://www.lillydirect.com/zepbound
NovoCare — Wegovy (semaglutide) — Manufacturer savings program ($149–349/month) https://www.novocare.com/patient/medicines/wegovy.html
Orforglipron — Eli Lilly oral GLP-1 — What to know about orforglipron (small-molecule oral GLP-1 agonist, pending FDA approval) https://www.lilly.com/news/stories/what-to-know-about-orforglipron

Our Sponsors:
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Factor: http://factormeals.com/bbm50off
* Check out Quince: https://quince.com/bbm

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

You can have a completely normal BMI and be on your way to cardiovascular disease, type 2 diabetes, and metabolic syndrome without triggering a single alert on a standard health screening. The fat that predicts metabolic risk most accurately isn't the fat your scale or your doctor is tracking. Dr. Jordan Feigenbaum breaks down the science of visceral fat — what it is, how it causes disease, how to measure it correctly at home for free, and what the evidence actually shows about exercise, GLP-1 medications, and testosterone.

Timestamps:

00:00:00 Cold Open: The Visceral Fat Finding
00:00:49 The Scale Problem — What Body Weight Actually Measures
00:03:50 What Is Visceral Fat — and Why It's Not Just "Belly Fat"
00:05:04 Three Competing Theories: How Visceral Fat Actually Causes Disease
00:08:35 Adipokines: PAI-1, Angiotensinogen, and What Happens When Adiponectin Drops
00:09:52 How to Measure: Three Sites That Don't Give the Same Number
00:14:30 Clinical Thresholds, Ethnic Adjustments, and the Waist-to-Height Ratio
00:15:45 The Weight-to-Waist Ratio: Tracking the Quality of Your Fat Loss
00:19:20 Sleep, Cortisol, and Why the Hormonal Environment Has to Support the Work
00:21:24 Why Exercise Reduces Visceral Fat 6× More Than Diet Alone
00:22:02 Mechanism 1 — Beta-3 Adrenergic Receptors and Preferential Visceral Fat Mobilization
00:24:10 Mechanism 2 — Myokines: The Fat-Burning Signal Only Contracting Muscle Can Send
00:26:21 GLP-1 Agonists and Body Composition: What the Clinical Trials Actually Show
00:28:05 DXA's Blind Spot: Myosteatosis, Glycogen, and Why Lean Mass Numbers Are Inflated
00:30:10 SEMALEAN, the BELIEVE Trial, and the 1-in-10 Reality of Long-Term Lifestyle Programs
00:33:15 Testosterone, Visceral Fat, and the Aromatase Feed-Forward Loop
00:36:05 Three Testosterone Ranges: Deficient, Eugonadal, and Supraphysiological
00:38:05 The Bhasin 4-Group Study — and Why AAS Are a Class, Not a Synonym for TRT
00:39:33 Tesamorelin: The GHRH Analogue That Selectively Targets Visceral Fat
00:40:53 Practical Framework: What to Measure, When, and What to Do
00:43:20 Key Takeaways

Next Steps

For evidence-based resistance training programs: barbellmedicine.com/training-programs
For individualized training consultation: barbellmedicine.com/coaching
Explore our full library of articles on health and performance: barbellmedicine.com/resources
To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/
To consult with Drs. Baraki or Feigenbaum email us at [email protected]
Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/

Resources:

https://pubmed.ncbi.nlm.nih.gov/11502820/
https://pubmed.ncbi.nlm.nih.gov/33567185/
https://pubmed.ncbi.nlm.nih.gov/35658024/
https://pubmed.ncbi.nlm.nih.gov/40318682/
https://pubmed.ncbi.nlm.nih.gov/41068996/
https://pubmed.ncbi.nlm.nih.gov/41772149/
https://pubmed.ncbi.nlm.nih.gov/23944298/
https://pubmed.ncbi.nlm.nih.gov/20948519/
https://pubmed.ncbi.nlm.nih.gov/27213481/
https://pubmed.ncbi.nlm.nih.gov/23303913/

Our Sponsors:
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Factor: http://factormeals.com/bbm50off
* Check out Quince: https://quince.com/bbm

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy